A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Exclusion Criteria

• •Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
• •Have inflammatory breast cancer
• •Have clinical evidence or a history of central nervous system (CNS) metastasis
• •Are currently receiving or have previously received endocrine therapy for locoregionally recurrent or metastatic breast cancer
• •Have received prior (neo)adjuvant endocrine therapy with a disease-free interval ≤12 months from completion of treatment
• •Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer
• •Have received prior treatment with everolimus
• •Have received prior treatment with any cyclin-dependent kinase (CDK) 4/6 inhibitor (or participated in any CDK4/6 inhibitor clinical trial for which treatment assignment is still blinded)
• •Have initiated bisphosphonates or approved receptor activator of nuclear factor kappa-B ligand (RANK-L) targeted agents \<7 days prior to randomization
• •Are currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study
• •Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of randomization for a nonmyelosuppressive or myelosuppressive agent, respectively
• •Have had major surgery within 14 days prior to randomization